MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: a cohort study

Lancet Neurology

Volumn 5, Issue 8, 2006, Pages 661-667

  Köhrmann, Martin ^a,c   Jüttler, Eric ^a   Fiebach, Jochen B ^a,b   Huttner, Hagen B ^a,c   Siebert, Stefan ^a   Schwark, Christian ^a   Ringleb, Peter A ^a   Schellinger, Peter D ^a,c   Hacke, Werner ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

AGED; ALGORITHM; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; STROKE; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

AGED; AGED, 80 AND OVER; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 33745949968     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(06)70499-9     Document Type: Article

References (30)

1. The ATLANTIS, ECASS, and NINDS rt-PA Study Group investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363 (2004) 768-774
2. Rother J., Schellinger P., Gass A., et al. Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke <6 hours. Stroke 33 (2002) 2438-2445
3. Schellinger P., Jansen O., Fiebach J., et al. Monitoring intravenous recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI. Stroke 31 (2000) 1318-1328
4. Parsons M., Barber P., Chalk J., et al. Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol 51 (2002) 28-37
5. Schellinger P., Fiebach J., Jansen O., et al. Stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia. Ann Neurol 49 (2001) 460-469
6. Schellinger P., Jansen O., Fiebach J., et al. Feasibility and practicality of MR imaging of stroke in the management of hyperacute cerebral ischemia. AJNR Am J Neuroradiol 21 (2000) 1184-1189
7. Kidwell C., Alger J., and Saver J. Beyond mismatch: evolving paradigms in imaging the ischemic penumbra with multimodal magnetic resonance imaging. Stroke 34 (2003) 2729-2735
8. Davis S., Donnan G., Butcher K., and Parsons M. Selection of thrombolytic therapy beyond 3 h using magnetic resonance imaging. Curr Opin Neurol 18 (2005) 47-52
9. Buckley B., Wainwright A., Meagher T., and Briley D. Audit of a policy of magnetic resonance imaging with diffusion-weighted imaging as first-line neuroimaging for in-patients with clinically suspected acute stroke. Clin Radiol 58 (2003) 234-237
10. Kidwell C., Chalela J., Saver J., et al. Comparison of MRI and CT for detection of acute intracerebral hemorrhage. JAMA 292 (2004) 1823-1830
11. Hjort N., Butcher K., Davis S., et al. Magnetic resonance imaging criteria for thrombolysis in acute cerebral infarct. Stroke 36 (2005) 388-397
12. Schellinger P., Fiebach J., and Hacke W. Imaging-based decision making in thrombolytic therapy for ischemic stroke: present status. Stroke 34 (2003) 575-583
13. Hacke W., Albers G., Al-Rawi Y., et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36 (2005) 66-73
14. Fiebach J., Schellinger P., Jansen O., et al. CT and diffusion-weighted MR imaging in randomized order: diffusion-weighted imaging results in higher accuracy and lower interrater variability in the diagnosis of hyperacute ischemic stroke. Stroke 33 (2002) 2206-2210
15. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 (1995) 1581-1587
16. Hacke W., Kaste M., Bogousslavsky J., et al. European Stroke Initiative Recommendations for Stroke Management-update 2003. Cerebrovasc Dis 16 (2003) 311-337
17. Hill M., and Buchan A. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 172 (2005) 1307-1312
18. Albers G., Bates V., Clark W., Bell R., Verro P., and Hamilton S. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 283 (2000) 1145-1150
19. Graham G. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke 34 (2003) 2847-2850
20. Kang D., Chalela J., Dunn W., and Warach S. MRI screening before standard tissue plasminogen activator therapy is feasible and safe. Stroke 36 (2005) 1939-1943
21. Larrue V., von Kummer R., Muller A., and Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 32 (2001) 438-441
22. Clark W., Wissman S., Albers G., Jhamandas J., Madden K., and Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 282 (1999) 2019-2026
23. Ribo M., Molina C., Rovira A., et al. Safety and efficacy of intravenous tissue plasminogen activator stroke treatment in the 3- to 6-hour window using multimodal transcranial Doppler/MRI selection protocol. Stroke 36 (2005) 602-606
24. Kidwell C., Saver J., Villablanca J., et al. Magnetic resonance imaging detection of microbleeds before thrombolysis: an emerging application. Stroke 33 (2002) 95-98
25. Barber P., Parsons M., Desmond P., et al. The use of PWI and DWI measures in the design of "proof-of-concept" stroke trials. J Neuroimaging 14 (2004) 123-132
26. Darby D., Barber P., Gerraty R., et al. Pathophysiological topography of acute ischemia by combined diffusion-weighted and perfusion MRI. Stroke 30 (1999) 2043-2052
27. Read S., Hirano T., Abbott D., et al. The fate of hypoxic tissue on 18F-fluoromisonidazole positron emission tomography after ischemic stroke. Ann Neurol 48 (2000) 228-235
28. Bruno A., Levine S., Frankel M., et al. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology 59 (2002) 669-674
29. Parsons M., Barber P., Desmond P., et al. Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study. Ann Neurol 52 (2002) 20-28
30. Ribo M., Molina C., Montaner J., et al. Acute hyperglycemia state is associated with lower tPA-induced recanalization rates in stroke patients. Stroke 36 (2005) 1705-1709